Top Markets
Coin of the day
Arch Biopartners Inc. Arch Biopartners Inc.

Arch Biopartners Inc.

ARCH
Rangering i aksjer #25412
Arch Biopartners Inc. is a biotechnology firm dedicated to devising... Arch Biopartners Inc. is a biotechnology firm dedicated to devising groundbreaking solutions for both medical and commercial applications. A significant focus for the company is the advancement of Metablok, a key therapeutic agent designed to address or avert dipeptidase-1 driven inflammation in critical organs such as the lungs, liver, and kidneys. This inflammatory response can lead to profound organ dysfunction or complete failure, particularly in conditions like sepsis and COVID-19. Moreover, Arch Biopartners is developing AB569, an experimental medication intended to combat antibiotic-resistant bacterial infections, primarily through topical application on wounds. Their innovative product pipeline also features Borg, a specialized peptide-solid surface interface developed to hinder biofilm formation and lessen material corrosion. Lastly, MetaMx involves synthetic compounds engineered to target the cells that initiate brain tumors and invasive glioma cells. The company's operations are based out of Toronto, Canada.
Aksjekurs
$0.73393689
Sist synkronisert: 2026-08-20
Markedsverdi
$49.86M
Endring (1 dag)
-8.26%
Endring (1 år)
-38.15%
Land
CA
Handel Arch Biopartners Inc. (ARCH)

Kategori

Inntekter for Arch Biopartners Inc. (ARCH)
Inntekter i Aug 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til Arch Biopartners Inc. er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Arch Biopartners Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$12.62B -
US
$6.02B -
NL
$15.70B -
AU
- -
CH
$2.23B -
US